Some of these shared loci were associated with higher BMI, but some were linked to lower BMI, particularly those also linked to schizophrenia.
A genome-wide association study meta-analysis of eight psychiatric conditions led to new and known risk loci, and revealed three distinct groups of conditions.
SelectHealth will cover PGx testing for Intermountain employees and beneficiaries with major depressive disorder who have failed treatment.
In Nature this week: residual protein expression uncovered for a third of CRISPR targets, and more.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
Researchers also uncovered associations between any psychotic experience and the genetic liability for schizophrenia, major depressive disorder, and bipolar disorder.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.